Literature DB >> 28786492

Cerebellar lesions are associated with TSC2 mutations in tuberous sclerosis complex: a retrospective record review study.

Susana Boronat1,2, Elizabeth Anne Thiele1, Paul Caruso3.   

Abstract

AIM: Cerebellar lesions are present in approximately 30% of patients with tuberous sclerosis complex. Although several prior studies have characterized these lesions, our study provides the first description of the specific distribution of these lesions within the cerebellum and the first genotype-phenotype correlation yet to be published.
METHOD: We retrospectively reviewed magnetic resonance images from 220 paediatric and adult patients with tuberous sclerosis complex (95 males, 125 females; mean age 22.7y, range 9mo-81y). Sex, age, and genotype of patients with cerebellar lesions were recorded and specific characteristics, including signal intensity, number, shape, presence of enhancement, calcification or haemorrhage, and location within the cerebellar lobules were noted.
RESULTS: Fifty-eight patients (26.4%) had 106 cerebellar lesions (62 right, 44 left). The mean number of cerebellar lesions per patient was 1.8 (range 1-6). Enhancement was present in 42.4% of lesions and folial retraction in 84%. Calcification was detected in 86.8% of lesions. Patients with calcified lesions were older (mean age 21.6y) than patients without calcification (11.5y). TSC2 mutations were detected in 41/42 (97.6%) of patients with cerebellar tubers who had genetic testing and one patient had no mutation identified. None of the patients had TSC1 mutation.
INTERPRETATION: We provide new information regarding cerebellar lesions in tuberous sclerosis complex: cerebellar lesions are significantly much more frequent in patients with TSC2 mutations than TSC1 mutations or patients with no mutation identified, and Crus II is the most frequent location of cerebellar lesions. New studies are needed to assess the clinical significance of these lesions.
© 2017 Mac Keith Press.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28786492     DOI: 10.1111/dmcn.13499

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  5 in total

1.  Calcitriol Reverses the Down-Regulation Pattern of Tuberous Sclerosis Complex Genes in an In Vitro Calcification Model.

Authors:  Eraldo Fonseca Dos Santos Junior; Roberta Rodrigues de Lemos Gitirana; Darlene Paiva Bezerra; João Ricardo Mendes de Oliveira
Journal:  J Mol Neurosci       Date:  2017-12-11       Impact factor: 3.444

2.  Rhinencephalon changes in tuberous sclerosis complex.

Authors:  Renzo Manara; Davide Brotto; Samuela Bugin; Maria Federica Pelizza; Stefano Sartori; Margherita Nosadini; Sara Azzolini; Giorgio Iaconetta; Cecilia Parazzini; Alessandra Murgia; Angela Peron; Paola Canevini; Francesca Labriola; Aglaia Vignoli; Irene Toldo
Journal:  Neuroradiology       Date:  2018-06-17       Impact factor: 2.804

Review 3.  A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC).

Authors:  Johann Philipp Zöllner; David Neal Franz; Christoph Hertzberg; Rima Nabbout; Felix Rosenow; Matthias Sauter; Susanne Schubert-Bast; Adelheid Wiemer-Kruel; Adam Strzelczyk
Journal:  Orphanet J Rare Dis       Date:  2020-01-21       Impact factor: 4.123

4.  TSC1 and TSC2 Genotype in Tuberous Sclerosis Complex: Are Other Manifestations of this Multisystem Disease Affected by Genotype?

Authors:  Thomas N Darling; Elizabeth A Thiele; Joel Moss
Journal:  Ann Am Thorac Soc       Date:  2021-05

Review 5.  Diagnostic Approach to Macrocephaly in Children.

Authors:  Andrea Accogli; Ana Filipa Geraldo; Gianluca Piccolo; Antonella Riva; Marcello Scala; Ganna Balagura; Vincenzo Salpietro; Francesca Madia; Mohamad Maghnie; Federico Zara; Pasquale Striano; Domenico Tortora; Mariasavina Severino; Valeria Capra
Journal:  Front Pediatr       Date:  2022-01-14       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.